Analysts expect MannKind Corp to report Q3 2026 revenue of approximately $107.74 million and an EPS of -$0.08, with the current stock price of $3.50 trading well below the average analyst price target of $8.32.
The primary focus for this report is the commercial performance of Furoscix ReadyFlow and its contribution toward the company's reaffirmed 2026 full-year revenue guidance of $110-$120 million.
Investors are also closely monitoring the early-stage launch traction of pediatric Afrezza following its FDA approval in May 2026, alongside updates on the MNKD-101 Phase 3 global trial. The company's ability to diversify revenue streams beyond Tyvaso DPI royalties remains central to the long-term bullish thesis for the stock.